Management of hepatitis C genotype 4 in the directly acting antivirals era

BMJ Open Gastroenterology

Volumn 3, Issue 1, 2016, Pages

  Hathorn, Emma ^a   Elsharkawy, Ahmed M ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR PLUS BECLABUVIR PLUS DACLATASVIR; DACLATASVIR; ELBASVIR PLUS GRAZOPREVIR; GLECAPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; PARITAPREVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PIBRENTASVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; VELPATASVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CHRONIC KIDNEY FAILURE; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; COMORBIDITY; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; HEALTH CARE ACCESS; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 85038904857     PISSN: None     EISSN: 20544774     Source Type: Journal    
DOI: 10.1136/bmjgast-2016-000112     Document Type: Article

References (80)

1. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146:1176-92.
2. Foster GR. Shorter treatments for hepatitis C: another step forward? Lancet 2015;385:1054-5.
3. Feld JJ. The beginning of the end: what is the future of interferon therapy for chronic hepatitis C? Antiviral Res 2014;105:32-8.
4. Kohli A, Osinusi A, Sims Z, et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 2015;385:1107-13.
5. Abdel-Razek W, Waked I. Optimal therapy in genotype 4 chronic hepatitis C: finally cured? Liver Int 2015;35(Suppl 1):27-34
6. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61 (1 Suppl): S45-57.
7. Bruggmann P, Berg T, Ovrehus AL, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014;21 (Suppl 1):5-33.
8. Wedemeyer H, Duberg AS, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014;21 (Suppl 1):60-89.
9. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31 (Suppl 2):61-80.
10. Abd Elrazek AE, Bilasy SE, Elbanna AE, et al. Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis. Medicine (Baltimore) 2014;93:e204.
11. Waked I, Doss W, El-Sayed MH, et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol 2014;15:45-52.
12. Karoney MJ, Siika AM. Hepatitis C virus (HCV) infection in Africa: a review. Pan Afr Medical J 2013;14:44.
13. Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 2014;39:137-47.
14. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
15. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
16. Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012;56:2039-50.
17. El Raziky M, Fathalah WF, El-Akel WA, et al. The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study. Hepatitis Monthly 2013;13:e10069.
18. Esmat G, El Kassas M, Hassany M, et al. How to optimize HCV therapy in genotype 4 patients. Liver Int 2013;33(Suppl 1):41-5.
19. Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007;46:1732-40.
20. Roulot D, Bourcier V, Grando V, et al. Observational VHCSG. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007;14:460-7.
21. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-82.
22. Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009;136:1618-1628.e2.
23. Lenz O, Vijgen L, Berke JM, et al. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatology 2013;58:445-51.
24. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
25. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013;381:2100-7.
26. Moreno C, Hezode C, Marcellin P, et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4. J Hepatol 2015;62:1047-55..
27. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384:403-13.
28. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146:1669-1679.e3.
29. Asseleh T, Moreno C, Sarrazin C, et al. High efficacy of a 12-week simeprevir plus pegylated interferon alfa 2a/ribavirin regimen in treatment naïve patients with chronic HCV genotype 4 infection and mild-to-moderate fibrosis. Hepatology 2015;62:792A.
30. Hézode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2014;64: 948-56.
31. Jensen D, Sherman KE, Hezode C, et al. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol 2015;63:30-7.
32. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015;385:1124-35.
33. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014;348:g3308.
34. Kayali Z, Schmidt WN. Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. Pharmgenomics Pers Med 2014;7:387-98.
35. Bourliere M, Oules V, Ansaldi C, et al. Sofosbuvir as backbone of interferon free treatments. Dig Liver Dis 2014;46(Suppl 5): S212-220.
36. Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015;62:1040-6.
37. Esmat GE, Shiha G, Omar RF, et al. Sofosbuvir Plus Ribavirin in the Treatment of Egyptian Patients with Chronic Genotype 4 HCV. Hepatology 2014;60(4 Suppl):133A.
38. Kapoor R, Kohli A, Sidhartan S, et al. All Oral Treatment for Genotype 4 Chronic Hepatitis C Infection with Sofosbuvir and Ledipasvir: Interim Results from the NIAID SYNERGY Trial. Hepatology 2014;60(4 Suppl):91A.
39. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93.
40. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370: 1889-98.
41. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-65.
42. Lawitz E, Matusow G, DeJesus E, et al. A Phase 3 study of 12-weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or treatment experienced patients with chronic HCV genotype 1 infection and cirrhosis: (OPTIMIST 2). J Hepatol 2015;62:S264-265.
43. El Raziky M, Gamil M, Hammad R, et al. Treatment of hepatitis C genotype 4 patients with simeprevir and sofosbuvir: Preliminary results from a phase IIa, partially randomised, open-label trial conducted in Egypt (OSIRIS). Hepatology 2015;62(1 Suppl):145A.
44. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-21.
45. Lawitz E, Poordad F, Gutierrez J, et al. SVR12 results from the Phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease. Hepatology 2015;62(1 Suppl):62A.
46. Nakamoto S, Kanda T, Wu S, et al. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014;20:2902-12.
47. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1,2,4,5 and 6 infection. N Engl J Med 2015;373:2599-607.
48. Gentile I, Buonomo AR, Borgia G. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther 2014;12:1033-43.
49. Stirnimann G. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opin Pharmacother 2014;15:2609-22.
50. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial. JAMA 2015;313:1223-31.
51. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-603.
52. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-92.
53. Trivella JP, Gutierrez J, Martin P. Dasabuvir: a new direct antiviral agent for the treatment of hepatitis C. Expert Opin Pharmacother 2015;16:617-24.
54. Pol S, Reddy KR, Baykal T, et al. Interferon-Free Regimen of Ombitasvir and ABT-450/r With or Without Ribavirin in Patients with HCV Genotype 4 Infection: PEARL-1 Study Results. Hepatology 2014;60(4 Suppl):1129A.
55. Abbvie. Viekirax Product Summary. 2014. http://www.viekiraxexviera.co.uk/prescribing-information.html
56. Asselah T, Hassaneln TI, Qaqish RB, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis (AGATE-1). Hepatology 2015;62(1 Suppl): 119A.
57. Esmat G, Doss W, Qaqish RB, et al. Efficacy and safety of co-formulated ombitasvir/paritaprevir/ritonavir with ribavirin in adults with chronic HCV genotype 4 infection without cirrhosis and with compensated cirrhosis in Egypt (AGATE-II). Hepatology 2015;62 (1 Suppl):118A.
58. Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014;146:420-9.
59. Hassanein T, Sims KD, Bennett M, et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol 2015;62:1204-6.
60. De Luca A, Bianco C, Rossetti B. Treatment of HCV infection with the novel NS3/4A protease inhibitors. Current Opin Pharmacol 2014;18:9-17.
61. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2014;385:1075-86.
62. Poordad F, Lawitz E, Gutierrez JA, et al. C-SWIFT: Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Sofosbuvir in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection, With and Without Cirrhosis, for Durations of 4, 6, or 8 Weeks (Interim Results). Hepatology 2014;60(Suppl 1):S192-3.
63. Asselah T, Reesink H, Gerstoft J, et al. High efficacy of elbasvir and grazoprevir with or without ribavirin in 103 treatment-naïve and experienced patients with HCV genotype 4 infection: a pooled analysis. Hepatology 2015;62(1 Suppl):340A.
64. Ng T, Pilot-Matias T, Lu L, et al. A Next Generation HCV DAA Combination: Potent Pangenotypic Inhibitors ABT-493 and ABT-530 with High Barriers to Resistance. Hepatology 2014;(Suppl 1):1148A.
65. Gane EJ, Pianko S, Roberts SK, et al. High Efficacy of an 8-Week 3-Drug Regimen of Grazeoprevir/MK-8408/MK-3682 in HCV Genotype 1,2 and 3-infected patients: SVR24 Data from the Phase- 2 C-CREST 1 and 2 Studies. J Hepatol 2016;64:S759.
66. Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014;147:132-142.e4.
67. Afdhal N, Everson G, Calleja JL, et al. Sofosbuvir and Ribavirin for the Treatment of Chronic HCV with Cirrhosis and Portal Hypertension with and without Decompensation: Early Virological Response and Safety J Hepatology 2014;60:S28.
68. Flamm S, Everson GT, Charlton M, et al. Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Decompensated Cirrhosis: Pre-liminary Results of a Prospective, Multicenter Study. Hepatology 2014;60(Suppl 1):320A.
69. Leroy V, Hezode C, Metivier S, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV infection and decompensated cirrhosis: interim analysis of a French multicentre compassionate use programme. http://ilc-congress.eu/wp-content/uploads/2016/abstracts/flipbook/mobile/index.html#p=708 (accessed 4 Aug 2016).
70. Cheung MCM, Walker AJ, Hudson BE, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-7.
71. Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment ir end-stage renal disease. Gastroenterology 2016;150:1590-8.
72. Roth DR, Nelson DR, Bruchfield A, et al. Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386:1537-45.
73. EASL. Recommendations on treatment of hepatitis C. 2015. http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/recommendations-on-treatment-of-hepatitis-c-2015 (accessed 4 Aug 2016).
74. van der Meer AJ, Wedemeyer H, Feld JJ, et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 2014;312:1927-8.
75. Ford N, Swan T, Beyer P, et al. Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings. J Hepatol 2014;61(1 Suppl):S132-138.
76. Cooke GS, Hill AM. Diagnostics for resource-limited settings in the era of interferon-free HCV therapy. J Viral Hepat 2015;22:459-60.
77. Hepatitis C drug in India to cost Rs 49 lakh less than in US. The Times of India. India.
78. Svarovskaia ES, Gane E, Dvory-Sobol H. L159F and V321A sofosbuvir-associated hepatitis c virus NS5B substitutions. J Infect Dis 2016;213:1240-7.
79. Schnell G, Tripathi R, Beyer J, et al. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir. Antimicrob Agents Chemother 2015;59:6807-15.
80. AASLD. Recommendations for Testing, Managing, and Treating Hepatitis C. 2015. http://www.hcvguidelines.org/full-report-view (accessed 4 Aug 2016).